Home › Compare › MTPVY vs ABBV
MTPVY yields 10.16% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 3
Combined, MTPVY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTPVY + ABBV for your $10,000?
Métropole Télévision S.A. provides a range of programs, products, and services on various media. It operates through four segments: Television, Radio, Production and Audiovisual Rights, and Diversification. The company operates free-to-air channels, including M6, W9, 6TER, and Gulli; pay channels, such as Paris Première, Téva, sérieclub, Canal J, Tiji, M6 Music, MCM, MCM Top, and RFM TV; on-demand televisions comprising 6play, Gulli Max, and Gulli Replay; and advertising agency, as well as produces news magazines comprising Capital, Zone Interdite, Enquête Exclusive, 66 Minutes, and Enquêtes criminelles for W9. It also operates radio stations that include RTL, RTL2, and Fun Radio; distributes audiovisual film rights; and produces and co-produces films. In addition, the company engages in the TV channel broadcasting business; production, co-production, or co-distribution of short and long-playing formats, which comprise singles and albums, as well as compilations on physical and digital formats; and events and shows, including concerts, stand-up comedians, music shows, exhibitions, etc. Further, it engages in the program production, digital production and publishing, merchandising rights exploitation, estate agency, animated feature films production, Internet content and access provision, print publications, and teleshopping program activities. It also provides training and wholesale trade services; sells house; and develops cinematographic works. Métropole Télévision S.A. was incorporated in 1986 and is headquartered in Neuilly-sur-Seine, France.
Full MTPVY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.